Penwest Pharmaceuticals — Proxy Contest (May 2009)
32 slides from Penwest Pharmaceuticals's proxy contest presentation, May 20, 2009
Slide 1: Penwest Pharmaceuticals Co.: The Case for Change
Penwest Pharmaceuticals Co. (NASDAQ: PPCO): The Case for Change Tang Capital Partners, LP Perceptive Life Sciences Master Fund Ltd. May 2009
Slide 2: Disclaimer
Disclaimer In connection with Penwest Pharmaceutical Co.'s upcoming 2009 annual meeting of shareholders (the "Annual Meeting"), Tang Capital Partners, LP ("Tang Capital") and Perceptive Life Sciences Master Fund Ltd. ("Perceptive") have filed with the Securities and Exchange Commission (the "SEC") a
Slide 3: Executive Summary
Executive Summary • Tang Capital and Perceptive are the two largest shareholders of Penwest • Current leadership has failed to deliver value for shareholders • Penwest’s corporate governance is seriously lacking and structured to maintain status quo • We have both the incentive and expertise to turn
Slide 4: Background on Proxy Contest
Background on Proxy Contest Having become frustrated with the Company’s actions and obstructionist tactics, we are undertaking this proxy contest only as a last resort
Slide 5: Our Interests Are Aligned with Yours
Our Interests Are Aligned with Yours • Tang Capital and Perceptive: • Own 41.5% of the Company’s stock • Invested $45 million to obtain our position We have one interest in mind: maximize the value of Penwest stock so that we can maximize the return on our and your investment • Penwest’s officers an
Slide 6: We Have a Track Record of Making Money for Our Investors
In Contrast to Current Leadership, We Have a Track Record of Making Money for Our Investors • Tang Capital and Perceptive both have proven track records • This is not the case for Penwest • Ms. Jennifer Good has been CEO since June 7, 2006 • Stock price performance: down 89%, versus down 9% for the
Slide 7: What We Are Proposing and Why
What We Are Proposing and Why Because: • It is time Penwest is governed by individuals more focused on and more capable of delivering positive returns for shareholders • Penwest’s corporate governance is seriously lacking and structured to maintain status quo • We have a clear plan to maximize value
Slide 8: Proposal 1: Our Nominees
Proposal 1: Our Nominees
Slide 9: Kevin C. Tang
Kevin C. Tang Mr. Tang is the founder and manager of Tang Capital, an investment fund that invests in health care companies, and has an established record of delivering positive returns for its investors. He has eighteen years of experience evaluating biopharmaceutical companies in his current capac
Slide 10: Joseph Edelman
Joseph Edelman Mr. Edelman is the founder and manager of Perceptive, an investment fund that invests in life sciences companies. He has nineteen years of experience evaluating biopharmaceutical companies in his current capacity as portfolio manager and his prior capacity as a biotechnology investmen
Slide 11: Andrew D. Levin, M.D., Ph.D.
Andrew D. Levin, M.D., Ph.D. Dr. Levin is a Principal at Tang Capital and has considerable expertise in evaluating the technical aspects of drug discovery and development programs. Prior to joining Tang Capital in April 2008, he served as a Business Development Manager at Genzyme Corporation, a phar
Slide 12: Our Nominees Will Better Represent Your Interests
Our Nominees Will Better Represent Your Interests Our nominees have proven track records and deep experience evaluating all aspects of biopharmaceutical businesses and governing these businesses from the board
Slide 13: Proposals 2 and 3: Our Governance Changes
Proposals 2 and 3: Our Governance Changes
Slide 14: Penwest Has a History of Ignoring Shareholders' Interests
Penwest Has a History of Ignoring Shareholders’ Interests Penwest’s corporate governance is structured only to maintain the status quo The Company has a history of not only ignoring shareholder interests, but, worse yet, actively suppressing shareholder input to avoid accountability
Slide 15: Penwest Has a Staggered Board
Penwest Has a Staggered Board • Penwest’s staggered board entrenches officers and directors • With a staggered board, only a minority of directors, in this case three of nine, stand for election each year • Even with a vote of an overwhelming majority of shareholders, it is not possible to replace a
Slide 16: Penwest Reinstated Its Poison Pill
Penwest Reinstated Its Poison Pill • In response to our call for change, Penwest reinstated its poison pill to avoid accountability • Prevents us from acquiring more stock or any other shareholder from acquiring more than 15% of Penwest’s stock • Again, proxy advisory firms frown on such provisions
Slide 17: Penwest Is Manipulating Its Board Size
Penwest Is Manipulating Its Board Size • In response to our proxy, Penwest reduced the number of seats up for election to further reduce shareholder influence • Board took this action after the deadline for shareholder proposals • Would reduce seats up for election at 2009 annual meeting to 2 of 8 (
Slide 18: Why We Are Proposing Changes to the Company's Bylaws
Why We Are Proposing Changes to the Company’s Bylaws • Current leadership’s blatant attempts to further entrench itself and insulate itself from shareholder influence underscore the need for strong, independent, investor representation on the board • Unfortunately, as shareholders, we collectively a
Slide 19: Proposal 2: Minimizing Delay Tactics
Proposal 2: Minimizing Delay Tactics • We are proposing a bylaw amendment that will require Penwest to hold its annual meeting on April 30th of each year • As it currently stands, Penwest can: • Determine the date of the annual meeting with few restrictions • Withhold the announcement of the annual
Slide 20: Proposal 3: Ensuring Directors You Elect Are Heard
Proposal 3: Ensuring Directors You Elect Are Heard • We are proposing a bylaw amendment that will require certain actions of the board to obtain approval of either 75% or 81% of the board • Because we will represent only 25% or 33% of the board, we run risk of being shut out of major board decisions
Slide 21: Proposal 4: Our Shareholder Resolution
Proposal 4: Our Shareholder Resolution
Slide 22: Penwest Has One Principal Asset
Penwest Has One Principal Asset • Penwest has one principal asset: the royalty income stream on Opana ER that it receives from licensee Endo Pharmaceuticals • ~$19 million-$25 million this year • Royalty rate ~11% • ~$45 million-$55 million next year • Royalty rate ~22% • This income stream is entir
Slide 23: Penwest Spends Money Wastefully with No Regard for Shareholder Return
Penwest Spends Money Wastefully with No Regard for Shareholder Return Penwest’s spending of the cash flow generated by the Opana ER royalty income stream is wasteful and will provide a dramatically lower return than simply retaining funds for ultimate distribution to shareholders
Slide 24: Overhead Out of Control
Overhead Out of Control • Overhead: • Webster definition: business expenses (as rent, insurance or heating) not chargeable to a particular part of the work or product, i.e., money spent on activities that will result in no return to shareholders • 2009 overhead guidance: $14 million-$16 million • ~7
Slide 25: Sole R&D Program Lacks Foundation
Sole R&D Program Lacks Foundation . Current leadership is 0/4 in new drug development . Nalbuphine ER . PW4153 . PW4110 . Torsemide ER . Penwest’s A0001 lacks scientific and commercial foundation . Nothing more than a metabolite of vitamin E that has no patent protection . Is many years behind a com
Slide 26: Our Shareholder Resolution on the Future Direction of the Company
Our Shareholder Resolution on the Future Direction of the Company • NPV of Opana ER royalty income stream alone far exceeds market capitalization of the Company, which stands at $65 million • Only 1.2-1.4 times next year’s estimated royalty income • Because of Penwest’s wasteful spending, its stock
Slide 27: Under Our Plan, Penwest's NOLs Are Secure
Under Our Plan, Penwest’s NOLs Are Secure • Despite what Penwest has stated, NOLs would NOT be forfeited by pursuing our plan • Section 382 of Internal Revenue Code disallows use of NOLs if, within two years after change of control, a corporation does not continue as a business enterprise • BUT, und
Slide 28: We Have Specific Experience Implementing Our Plan
We Have Specific Experience Implementing Our Plan • Tang Capital has been a major shareholder of Ardea Biosciences, Inc. (NASDAQ: RDEA) for six years • Mr. Tang has been a director of Ardea for same period of time • In 2004, Ardea decided it was in best interest of shareholders to wind down its oper
Slide 29: We Have Specific Experience Implementing Our Plan (cont.)
We Have Specific Experience Implementing Our Plan (cont.) • In December 2006, Mr. Tang supervised redeployment of Ardea’s capital • Stock up 265% from where it traded when wind-down announced, versus down 10% for the NASDAQ Biotech Index RDEA Stock Price Performance Stock Price ($) 20 18 16 14 12 10
Slide 30: Why It Is Critical that You Vote on the Shareholder Resolution
Why It Is Critical that You Vote on the Shareholder Resolution Because Penwest’s board is staggered, we will not obtain a majority of the board even with your overwhelming support Therefore, it is critical that you cast your vote on this matter so that the board, through a mechanism that is quantita
Slide 31: Summary
Summary • Tang Capital and Perceptive are the two largest shareholders of Penwest • Current leadership has failed to deliver value for shareholders • Penwest’s corporate governance is seriously lacking and structured to maintain status quo • We have both the incentive and expertise to turn Penwest a
Slide 32: Contact Information
Contact Information The Altman Group 1200 Wall Street West , 3rd Floor Lyndhurst , NJ 07071 Shareholders call toll free: (866) 620-7619 Banks and brokers call collect: (201) 806-2214 Fax: (201) 460-0050 For more information, please visit: www.penwestchange.com